Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease.

Daisuke Fukamachi Yasuo OkumuraNaoya MatsumotoEizo TachibanaKoji OiwaMakoto IchikawaHironori HarutaKazumiki NomotoKen ArimaAtsushi Hirayama

Published in: Journal of interventional cardiology (2022)

The edoxaban monotherapy was shown to have acceptable clinical safety in patients with NVAF and stable CAD. The study was registered with the Japan Registry of Clinical Trials (jRCTs031180119).

Keyphrases

atrial fibrillation
clinical trial
venous thromboembolism
direct oral anticoagulants
combination therapy
open label
oral anticoagulants
left atrial appendage
coronary artery disease
heart failure
left atrial
percutaneous coronary intervention
phase ii
phase iii
double blind